Oncology ESMO 2024 - Daejin Abidoye At ESMO 2024, AbbVie presented new data across their solid tumour pipeline, displaying the company’s potential as an emerging leader in solid tumours.
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
